Rabbit Polyclonal CD160 Antibody

CD160 antibody targets the CD160 glycoprotein, a cell surface molecule belonging to the immunoglobulin superfamily. Initially identified as a receptor expressed on cytotoxic T cells and natural killer (NK) cells, CD160 interacts with ligands such as herpesvirus entry mediator (HVEM) and major histocompatibility complex (MHC) class I molecules. It plays dual roles in immune regulation, acting as a co-stimulatory or co-inhibitory receptor depending on cellular context and ligand engagement. CD160 is implicated in modulating T-cell exhaustion in chronic infections and cancer, where sustained signaling often correlates with impaired effector function. In NK cells, CD160 activation enhances cytotoxicity and cytokine production, suggesting a role in antiviral and antitumor responses. Structurally, CD160 exists as both a glycosylphosphatidylinositol (GPI)-anchored membrane protein and a soluble isoform, adding complexity to its functional diversity. Antibodies targeting CD160 have emerged as tools to investigate its biology and therapeutic potential. Blocking antibodies can disrupt CD160-HVEM interactions, potentially reversing T-cell exhaustion in chronic diseases. Conversely, agonist antibodies may enhance NK-mediated immunity. Challenges in CD160 research include understanding its tissue-specific signaling and reconciling contradictory roles in pro-inflammatory (e.g., atherosclerosis) versus immunosuppressive contexts. Recent studies also explore CD160's expression on regulatory T cells and gut-associated lymphoid tissue, hinting at broader immunomodulatory functions. Its therapeutic relevance is being evaluated in cancer immunotherapy and autoimmune disorders, though clinical applications remain experimental.